Skin Cancer News Staging systems were analyzed for specificity, positive predictive value, negative predictive value, concordance index, and other parameters.
The objective response rate was 12.5%, and the median progression-free survival was 2.6 months.
The median progression-free survival was 10.1 months with relatlimab-nivolumab and 4.6 months with nivolumab.
Higher intake of dietary fiber was linked to longer progression-free survival in melanoma patients on immune checkpoint blockade.
HLA-A*03 was associated with worse progression-free and overall survival.
Results of a 10-year retrospective study suggests a higher risk of nonmelanoma skin cancer in patients with PV or MF after ruxolitinib exposure.
Overall survival data were available for about half of the drugs.
Approval was based on data from the phase 3 KEYNOTE-716 trial, which enrolled 976 participants.
Researchers assessed the relationship between concomitant radiotherapy and ICI therapy and the need for corticosteroids in patients with lung cancer or melanoma.
Receiving at least 20% of infusions after 4:30 pm was associated with shorter survival.
The 3-year intracranial progression-free survival rate was 54% in asymptomatic patients and 18.9% in symptomatic patients.
Melanomas diagnosed through routine skin checks are associated with significantly lower all-cause mortality.
Less than 10% of radiotherapy recommendations in 2020 NCCN guidelines were category 1 recommendations.
Roughly half of patients diagnosed with skin cancer after an organ transplant developed a subsequent skin cancer within 2 years.
Vismodegib treatment in local advanced and metastatic basal cell carcinoma is assessed.
Talimogene laherparepvec improved recurrence-free and overall survival.
Mohs micrographic surgery defect sizes were 17% larger among Hispanic/Latino patients.
The sensitivity and specificity for detecting malignancy was 79.4% and 37.7%, respectively.
Relapse-free survival outcomes were similar between real-world and clinical trial patients.
The mortality rate of keratinocyte carcinoma was 1.8 times higher in men than women between 1998 and 2017.
Load More
